Literature DB >> 33467204

Immune Monitoring upon Treatment with Biologics in Sjögren's Syndrome: The What, Where, When, and How.

Joyce J B C van Beers1, Jan G M C Damoiseaux2.   

Abstract

Over the years, a wide variety of therapeutic antibodies has been successfully introduced in the auto-immunology clinic, and many more are on the way. Many of these treatments address either a pathogenic circulating molecule or a cell-bound molecule. Whereas addressing the former target results in neutralization of the soluble factor and binding to the latter target either inhibits cellular function or induces selective cell death. If this targeted molecule or cell is part of the immune system, this therapy evokes a state of immunodeficiency with infections as a possible consequence. Therefore, immune monitoring is needed to prevent such adverse side effects of immunotherapy. In this paper, different immunotherapies used in Sjögren's syndrome, as well as different approaches to monitoring the immune system, are discussed.

Entities:  

Keywords:  Sjögren’s disease; Sjögren’s syndrome; biologics; immune monitoring

Year:  2021        PMID: 33467204      PMCID: PMC7830440          DOI: 10.3390/biom11010116

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  82 in total

1.  Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.

Authors:  Rodrigo Guimaraes de Souza; Zhiyuan Yu; Michael E Stern; Stephen C Pflugfelder; Cintia S de Paiva
Journal:  J Ocul Pharmacol Ther       Date:  2018-06-29       Impact factor: 2.671

2.  The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.

Authors:  Wei Jiang; Lingshu Zhang; Yi Zhao; Xiong He; Chunrong Hu; Yi Liu
Journal:  Int Ophthalmol       Date:  2020-07-01       Impact factor: 2.031

Review 3.  Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.

Authors:  Keith A Sacco; Roshini S Abraham
Journal:  Immunotherapy       Date:  2018-03-23       Impact factor: 4.196

4.  The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials.

Authors:  Renaud Felten; Florence Scher; Jean Sibilia; Jacques-Eric Gottenberg; Laurent Arnaud
Journal:  Autoimmun Rev       Date:  2019-04-06       Impact factor: 9.754

Review 5.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 6.  Cytokines in Sjögren's syndrome.

Authors:  N Roescher; P P Tak; G G Illei
Journal:  Oral Dis       Date:  2009-06-10       Impact factor: 3.511

7.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors:  M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

Review 8.  Sjögren's syndrome: Old and new therapeutic targets.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  J Autoimmun       Date:  2019-12-09       Impact factor: 7.094

9.  Refractory Sjögren's syndrome myelopathy successfully treated with subcutaneous tocilizumab: A case report.

Authors:  Yuichi Ishikawa; Koto Hattori; Junichi Ishikawa; Michio Fujiwara; Yasuhiko Kita
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 10.  Immune monitoring using mass cytometry and related high-dimensional imaging approaches.

Authors:  Felix J Hartmann; Sean C Bendall
Journal:  Nat Rev Rheumatol       Date:  2019-12-31       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.